Bionano Genomics, Inc.
bionano.comWhat Do They Do?
Sells genome-mapping and DNA-preparation systems, genomic analysis software and laboratory services to research and clinical laboratories, researchers and clinicians.
10-K for FY2025, filed Mar 23, 2026We are a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in…View ↗
We develop, manufacture, market and sell OGM systems, including the Saphyr® system and the Stratys system, which deliver OGM data to enable…View ↗
We develop, manufacture, market and sell the Ionic® Purification system, which is able to deliver high quality DNA in a more natural…View ↗
We develop, manufacture, market and sell the VIA software which delivers genomic data interpretation solutions tailored for research use in…View ↗
Bionano Laboratories also provides laboratory services to clinicians, scientists, pharmaceutical companies, and others who are seeking to…View ↗
How Do They Make Money?
Customers buy instruments and consumables, generally paying when delivered; software is sold by subscription, while maintenance and support agreements pay over their terms. Hosted software also brings in fees as customers process purchased samples.
10-K for FY2025, filed Mar 23, 2026We generate product revenue from sales of our OGM and Ionic Purification systems and consumables, which includes our instruments, and our…View ↗
The Company recognizes a receivable when we have an unconditional right to payment, which is generally at the time of delivery of software…View ↗
Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title…View ↗
Revenue related to software license maintenance agreements is recognized over-time based on the contract term. Revenue recognized over-time…View ↗
Revenue for hosting arrangements is recognized over-time on a usage basis as the customer processes the number of genetic samples purchased…View ↗
Revenue from support and maintenance contracts and extended warranties is recognized over time based on the contract term, which represents…View ↗
-
10-K for FY2025, filed Mar 23, 2026
FY2025 revenue by product or service ↗
$28.5M
-
10-K for FY2025, filed Mar 23, 2026
$28.5M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Instruments
Mix
10-K for FY2025, filed Mar 23, 2026 |
22%
FY2022: 31%
|
Instruments, FY2025
$6.4M Sources
|
Mix |
|
Consumables
Sold outright
10-K for FY2025, filed Mar 23, 2026 |
49%
FY2022: 24%
|
Consumables, FY2025
$14M Sources
|
Sold outright |
|
Software
|
22%
FY2022: 18%
|
Software, FY2025
$6.4M Sources
|
|
|
Service and other revenue
|
6.2%
FY2022: 27%
|
Service and other revenue, FY2025
$1.8M Sources
|
Who Are Their Customers?
Customers include academic and government research laboratories, clinical laboratories, and pharmaceutical, biotechnology and contract research companies. Bionano sells directly in North America and Europe and through distributors in Asia-Pacific and selected other markets; its laboratory team also runs samples for researchers without an in-house system.
10-K for FY2025, filed Mar 23, 2026We generate product revenue from sales of our OGM and Ionic Purification systems and consumables, which includes our instruments, and our…View ↗
We sell our products through a direct sales force based in North America and Europe. Our sales strategy involves the use of a combination…View ↗
We sell our products through a network of distributors in the Asia-Pacific region and select other markets outside of North America and…View ↗
In addition, we maintain an applications lab team in San Diego, California composed of scientific experts who can transfer knowledge from…View ↗
Bionano Laboratories also provides laboratory services to clinicians, scientists, pharmaceutical companies, and others who are seeking to…View ↗
Do Revenues Turn Into Profits?
No. It lost $26.4M in FY2025.
10-K for FY2025, filed Mar 23, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$7.4MView ↗
- ▲ +8% (Loss)
- vs −$6.9M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 10, 2026
Open tableView ↗
-
Aug 10, 2026
Gave third-quarter and full-year revenue guidance
The company projected third-quarter revenue of $8.2 to $8.6 million and full-year revenue of $31 to $33 million.
Sources
8-K, filed Aug 10, 2026
Q3 2026 revenue guidance in the range of $8.2 to $8.6 million.View ↗
-
May 6, 2026
CEO was terminated and chairman became interim CEO
R. Erik Holmlin was terminated as CEO; chairman Al Luderer became interim CEO while the company searches for a permanent successor.
Sources
8-K, filed May 6, 2026
On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc. (the “Company”) R. Erik Holmlin, Ph.D. was terminated as the Company’s…View ↗
Growing. Revenue grew 59% in 4 years, from $18M in FY2021 to $28.5M in FY2025, about 12% a year.
OGM enters the software workflow
The earlier report said the company was developing software to incorporate OGM data; the latest describes VIA as analyzing OGM alongside sequencing and microarray data.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 23, 2026Our software delivers genomic data interpretation solutions tailored for research use in cytogenomics and molecular pathology labs in…View ↗
We develop, manufacture, market and sell the VIA software which delivers genomic data interpretation solutions tailored for research use in…View ↗
Narrower laboratory testing menu
The earlier report described clinical testing for developmental conditions and blood cancers alongside a muscular-dystrophy test; the latest says it phased out the former offerings and focuses on an OGM-based test for muscular dystrophy.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 23, 2026Our Bionano Laboratories business provides proprietary genetic clinical testing services for individuals demonstrating clinical…View ↗
Our Bionano Laboratories business has developed and provides an OGM-based LDT for facioscapulohumeral muscular dystrophy type 1 (“FSHD1”)…View ↗
Adds another OGM system
The earlier report described Saphyr as its OGM system; the latest also describes the Stratys system, expanding the range of systems offered.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 23, 2026We market and sell the Saphyr® system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of…View ↗
We develop, manufacture, market and sell OGM systems, including the Saphyr® system and the Stratys system, which deliver OGM data to enable…View ↗
Loading...
